2679-14-3

Basic information

• Product Name: 3-(METHYLAMINO)PROPIONIC ACID
• Synonyms: 3-(METHYLAMINO)PROPIONIC ACID;RARECHEM AL BO 1090;N-METHYL-BETA-ALANINE;N-Methyl-b-alanine;N-Methyl-b-aminopropionicAcid;N-Methyl--aminopropionic Acid;beta-alanine, N-methyl-;N-methyl-beta-alanine(SALTDATA: HCl)
• CAS NO: 2679-14-3
• Molecular Formula: C₄H₉NO₂
• Molecular Weight: 103.12
• Product Categories: Amino Acids & Derivatives
• Mol File: 2679-14-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 164-166°C
• Boiling Point: 217℃
• Flash Point: 85℃
• Appearance: white solid
• Density: 1.052
• Vapor Pressure: 0.051mmHg at 25°C
• Refractive Index: 1.4451
• Storage Temp.: -20°C Freezer
• Solubility: Methanol (Slightly), Water (Slightly)
• PKA: 3.66±0.12(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: 3-(METHYLAMINO)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(METHYLAMINO)PROPIONIC ACID(2679-14-3)
• EPA Substance Registry System: 3-(METHYLAMINO)PROPIONIC ACID(2679-14-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• HazardClass: IRRITANT
• Hazardous Substances Data: 2679-14-3(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Parakeratosis inhibitor, commonly found in skin care products to shrink pores.

InChI:InChI=1/C4H9NO2/c1-5-3-2-4(6)7/h5H,2-3H2,1H3,(H,6,7)

Upstream product

• 24549-12-0 methyl 3-(methylamino)propanoate 
• 590-92-1 3-Bromopropionic acid 
• 74-89-5 methylamine 
• 141-76-4 3-iodopropanoic acid 
• 693-05-0 N-(2-cyanoethyl)-N-methylamine 
• 7732-18-5 water 
• 2679-13-2 1-methylazetidine-2-one 
• 107-95-9 3-amino propanoic acid 
• 149692-49-9 3-(N-Benzyl-N-methylamino)propionsaeure 
• 107-94-8 chloropropionic acid 
• 50-00-0 formaldehyd 

Downstream Products

• 2213-08-3 ethyl 3-methylaminopropionate 
• 35404-55-8 N-Methyl-N-amidino-β-alanin 
• 124072-61-3 N-t-butoxycarbonyl-N-methyl-β-alanine 
• 1329169-84-7 3-({(S)-3-tert-butoxycarbonylamino-3-[4-[4-methoxycarbonylamino-2-(2,2,2-trifluoroacetylamino)phenyl]-1-(2-trimethylsilanylethoxymethyl)-1H-imidazol-2-yl]propyl}methylamino)propionic acid 
• 1360817-14-6 C₂₆H₂₄FN₃O₂S 
• 33456-79-0 1-(2-carboxyethyl)-3-(3,4-dichlorophenyl)-1-methylurea 
• 74-85-1 ethene 
• 63192-23-4 N,N-bis(2,7-octadienyl)methylamine 
• 99987-01-6 N-methyl-N-(toluene-4-sulfonyl)-β-alanine 

Relevant articles and documents

New cyclic peptides from the Indonesian sponge Theonella swinhoei

Three new cyclic peptides, barangamides B, C, and D and a new depsipeptide, theonellapeptolide IIe as well as known theonellapeptolides Ia, Id, Ie, IId have been isolated from the sponge Theonella swinhoei collected in Baranglompo Island, Indonesia The structures of barangamides were elucidated by interpretation of NMR data and application of Marfey's method. The structure of theonellapeptolide IIe, a mixture of several conformers showing complex NMR spectra, was determined by MS analysis of a ring-opened product and by chemical reaction. Some of the theonellapeptolides showed mild immunosuppressive activity, while barangamide A was inactive. (C) 2000 Elsevier Science Ltd.

Adenine receptor ligands

The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs.

WRINKLE-IMPROVING AGENT

The invention provides a novel wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific β-alanine derivatives and the salts thereof was developed.